Celldex Therapeutics, Inc. (CLDX) Return on equity 2016–2025
Celldex Therapeutics, Inc. (CLDX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-49.1%FY2025 · since FY2016: -48.4% → -49.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -49.1% | -28.0 pp |
| FY2024 | -21.1% | +11.8 pp |
| FY2023 | -33.0% | +1.5 pp |
| FY2022 | -34.4% | -17.6 pp |
| FY2021 | -16.8% | +11.7 pp |
| FY2020 | -28.6% | +25.6 pp |
| FY2019 | -54.1% | +67.8 pp |
| FY2018 | -121.9% | -82.5 pp |
| FY2017 | -39.4% | +9.1 pp |
| FY2016 | -48.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice